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Abstract: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death 
in the US and a major worldwide healthcare problem. The pathophysiologic mechanisms that 
drive development and progression of this disease are complex and only poorly understood. 
While tobacco smoking is the primary risk factor, other disease processes also appear to play 
a role. Components of the innate immune system (eg, macrophages and neutrophils) have 
long been believed to be important in the development of COPD. More recent evidence also 
suggests involvement of the adaptive immune system in pathogenesis of this disease. Here we 
will review the literature supporting the participation of T-cells in the development of COPD, 
and comment on the potential antigenic stimuli that may account for these responses. We will 
further explore the prospective contributions of T-cell derived mediators that could contribute 
to the inﬂ  ammation, alveolar wall destruction, and small airway ﬁ  brosis of advanced COPD. 
A better understanding of these complex immune processes will lead to new insights that could 
result in improved preventative and/or treatment strategies.
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Chronic obstructive pulmonary disease (COPD) is characterized by expiratory airﬂ  ow 
limitation that is not fully reversible, is usually progressive, and is associated with an 
abnormal intrapulmonary inﬂ  ammatory response to noxious particles or gases (Rabe 
et al 2007). COPD is a leading cause of death worldwide, and one of the few diseases 
in which mortality rates continue to increase (Manino 2002; Rabe et al 2007). Manage-
ment of patients afﬂ  icted with COPD is often frustrating, and it is uncertain that any 
of the currently available treatments actually modify the natural history of the disease. 
While direct injury to airway and alveolar epithelium from chronic exposure to smoke 
is undoubtedly the primary risk factor for the development of COPD, the potential 
contributions of other disease mechanisms appear to be important. Individuals with 
COPD typically have at least a 10 pack-year history of tobacco smoking. However, 
only a minority of heavy smokers develop severe airﬂ  ow abnormalities, suggesting 
that the disease is not solely attributable to smoke exposure. Furthermore, COPD often 
progresses, and intrapulmonary inﬂ  ammation typically persists, despite removal of the 
inciting agent(s) with the cessation of smoking (Retamales et al 2001).
The presence of intrapulmonary inﬂ  ammation in COPD has been appreciated for 
many years, and accumulations and functions of activated macrophages and polymor-
phonuclear leukocytes (components of the innate immune system) have long been 
believed to be important in disease development (Brain 1980; Schleime 2005; Tetley 
2005; Quint and Wedzicha 2007). More recent reports have suggested that the adaptive International Journal of COPD 2008:3(4) 532
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immune response also contributes to the pathophysiology 
of COPD. The cellular effectors of adaptive immunity 
are lymphocytes (both B- and T-cells), and the distinctive 
hallmarks of this system include antigen speciﬁ  city, clonal 
expansions of antigen-activated lymphocytes, and the genera-
tion of immunologic memory (Monaco et al 2004). A greater 
understanding of adaptive immune processes in COPD could 
perhaps lead to more effective disease interdictions, including 
elimination or eradication of the antigen(s), induction of 
tolerance to the antigen(s), manipulations of immunoregula-
tory mechanisms, or perhaps targeted depletion of speciﬁ  c 
disease-associated lymphocyte subpopulations.
Here we will review some of the evidence supporting the 
hypothesis that T-cell responses are important in the patho-
genesis of COPD, comment on the potential contributions 
of individual T-lymphocyte subsets, and outline selected 
mediators elaborated by these cells.
Associations of   T -lymphocytes
with COPD
The presumed role of T-cells in COPD was ﬁ  rst suggested 
by histopathologic studies that found associations between 
disease severity and the extent of intrapulmonary lympho-
cyte inﬁ  ltrates. Finkelstein et al noted that lymphocytes and 
macrophages are the predominant cellular elements of the 
inﬂ  ammatory inﬁ  ltrates within airway walls of patients with 
COPD (Finkelstein et al 1995). These observations were 
extended by ﬁ  nding that numbers of CD8+ lymphocytes in 
COPD lungs were directly related to the degree of airﬂ  ow 
limitation (Figure 1) (Saetta et al 1998). Among many other 
analogous studies, the numbers of T-lymphocytes in surgical 
lung resections of patients with emphysema were shown to 
be signiﬁ  cantly increased, compared to ﬁ  ndings in smokers 
without evidence of airﬂ  ow obstruction or nonsmokers (Majo 
et al 2001). A recent comprehensive study of the morpho-
metric changes seen in the small airways of COPD patients 
further noted the relatively unique presence of sub-epithelial 
lymphoid aggregates, described as bronchus associated 
lymphoid tissue (BALT), and the number of these BALT 
lesions was associated with the severity of airﬂ  ow obstruction 
(Hogg et al 2004).
T-lymphocytes can cause tissue injuries either by 
direct cytolytic activities or through the secretion of 
pro-inﬂ  ammatory mediators that recruit and activate other 
immune cell types (eg, phagocytic cells and B-cells) (Monaco 
et al 2004). Pulmonary lymphocytes isolated from emphy-
sematous lung tissue are frequently activated (Sullivan et al 
2005) and capable of secreting mediators that have been 
implicated in the pathogenesis of COPD (Grumelli et al 
2004). T-cells transit between inﬂ  ammatory foci in organs 
and regional lymph nodes, and at least some proportion 
of these disease-speciﬁ  c lymphocytes also trafﬁ  c within 
lymphatic and blood circulations (Lehmann et al 2001). 
Our studies of peripheral blood T-lymphocytes in patients 
with COPD have shown peripheral T-cells (particularly 
CD8+) are more frequently activated and have increased 
productions of various mediators, and many of these T-cell 
abnormalities are highly correlated with disease severity 
(Gadgil et al 2006).
Animal models of emphysema further corroborate the 
importance of T-lymphocyte responses in the development 
of COPD. The potential for activated T-cells to cause lung 
injury in mice was evidenced after adoptive transfer of CD8+ 
T-cells with speciﬁ  cities for neoantigens that were expressed 
on alveolar epithelial cells (Enelow et al 1998). CD8+ 
T-lymphocytes were also recently shown to be critical for the 
induction of inﬂ  ammation and tissue destruction in a murine 
model of smoke-induced emphysema (Maeno et al 2007). In 
addition, adoptive transfers of syngeneic CD4+ lymphocytes 
that had been sensitized to endothelial cell antigens resulted 
in development of emphysema in naïve rats, thus highlighting 
the potential for CD4+ T-cell associated autoimmune disease 
processes in COPD (Taraseviciene-Stewart et al 2005).
CD4/CD8 T -cell subsets in COPD
The majority of studies using patient-derived specimens seem 
to indicate that CD8+ lymphocytes appear to play a particu-
larly important role in the development and/or progression of 
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Figure 1 Inverse relationship between the presence of CD8+ lymphocytes in the airway 
wall and forced expiratory volume in the ﬁ  rst second (FEV1) in smokers. Reprinted with 
permission from Saetta, et al 1998. Am J Respir Crit Care Med, 157:822–6. Copyright © 
1998 American Thoracic Society.International Journal of COPD 2008:3(4) 533
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COPD (Finkelstein et al 1995; O’Shaughnessy et al 1997; Di 
Stefano et al 1998; Majo et al 2001; Hogg et al 2004; Saetta 
et al 1998). Most (but not all) investigators have reported 
that COPD CD8+ lymphocytes secrete a Th1 predominant 
cytokine pattern that includes increased production of 
IFN-γ, interferon-inducible protein-10 (IP-10), and monokine 
induced by interferon-gamma (MIG). In turn, these media-
tors can cause tissue destruction through the upregulation of 
matrix metalloproteinase (MMP) production by macrophages 
and other immune effectors (Grumelli et al 2004; Manneo 
2007). CD8+ T-lymphocytes can also mediate cell-death 
directly through the secretion of cytotoxic mediators (eg, 
granzyme and perforins), as well as expression or secretion 
of Fas (Henkart 1994; Kojima et al 1994).
While the function of CD8+ lymphocytes are often high-
lighted in COPD studies, the potential contributions of CD4+ 
T-cells in the disease process also appear to be substantial. 
Although typically less extensive than CD8+ T-cell inﬁ  l-
trates, intraparenchymal CD4+ lymphocytes are also present 
in abnormally increased numbers within emphysematous 
lungs (Majo et al 2001), particularly in proximity to BALT 
(Hogg et al 2004).
CD4+ T-cells are largely responsible for orchestrating 
downstream immune processes by the release of activating 
cytokines, and are important if not critical in focusing and 
amplifying inﬂ  ammatory responses by other immune effector 
cells. As an example, actions of CD4+ T-cells are essential 
for the full development of adaptive immune cytotoxicity by 
priming (lowering thresholds of activation) and promoting 
the long-term survival of CD8+ T-cells. The facultative 
help provided by CD4+ lymphocytes is also important for 
the activation and differentiation of antibody-elaborating 
B-cells. This “help” is especially critical for induction of 
B-cells to undergo isotype switch from production of IgM to 
more potent and avidly-binding IgG antibodies, particularly 
against protein antigens.
We examined the possibility that CD4 T-cells could 
facilitate B-cell production of IgG autoantibodies in COPD 
patients. Somewhat to our surprise, we found that ∼70% of 
these patients had circulating IgG autoantibodies against 
epithelial cells, as ascertained by indirect immunoﬂ  uores-
cence assays, compared to 10% among non-smoking con-
trols and 13% of cigarette smokers without evidence of 
lung abnormalities (Feghali-Bostwick et al 2008). An even 
more highly sensitive and speciﬁ  c immunoprecipitation 
assay showed that 34 out of 35 COPD patients (97%) had 
autoreactive antibodies against a variety of cellular self-
antigens (Figure 2). Not only are circulating autoantibodies 
highly prevalent in COPD patients, but the immunoglobulins 
appeared likely to be pathogenic, as evidenced by ﬁ  ndings of 
immune complex deposition and complement activation in 
surgically resected end-stage COPD lungs, and the evident 
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Figure 2 Immunoprecipitation of autoantibodies in plasma samples of COPD patients. Bands represent autoantigens precipitated by autoantibodies present in COPD plasma 
specimens (composite ﬁ  gure). Similarly treated plasma samples from non-smokers are shown here as controls. The most highly prevalent autoantigens are highlighted and 
were shown by other means to be distinct from antigens involved in other known autoimmune syndromes. Individual lanes correspond to a patient sample. Reprinted with 
permission from Feghali-Bostwick, et al 2008. Am J Respir Crit Care Med, 177:156–63. Copyright © 2008 American Thoracic Society.
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ability of these autoantibodies to induce antibody dependent 
cell-mediated cytotoxicity (ADCC).
In addition to the generally potent pro-inﬂ  ammatory 
effects of CD4+ lymphocytes, a subset of these cells may 
also (and perhaps more favorably) inﬂ  uence the progres-
sion of immunologic diseases, including COPD, by acting 
to dampen the intensity of inﬂ  ammatory cascades. A small 
proportion of CD4+ T-lymphocytes with distinctive pheno-
typic characteristics have been shown to exert suppressive 
effects on inﬂ  ammatory processes common to many immu-
nologic and autoimmune diseases (Rouse 2007). However, 
the role of these regulatory T cells (Treg) in COPD has only 
recently become a topic of investigation. One contemporane-
ous study suggested that chronic cigarette exposure resulted 
in increased Treg populations in the bronchoalveolar lavage 
(BAL) of COPD patients, but these cells were paradoxically 
believed to be functionally impaired (Smyth et al 2007). 
Conversely, another recent investigation found decreased 
numbers of functionally intact Tregs in emphysematous lung 
tissue compared to healthy lungs (Lee et al 2007). Further 
investigations into the potential impact of Treg cells in the 
development of smoking related lung inﬂ  ammation and 
injury are necessary, and could have considerable eventual 
importance for development of novel therapeutics.
Peptide antigens – triggers
of adaptive immune activation
In the face of mounting evidence that T-lymphocytes likely 
participate in the pathogenesis of COPD, the circumstances 
that bring about initial activations of these cells remains 
a matter of speculation. A number of studies indicate that 
the lymphocyte proliferations seen in COPD patients are 
driven by speciﬁ  c peptide antigens. Identiﬁ  cation of these 
antigen(s) would have far-reaching importance for furthering 
our understanding of COPD, and almost certainly enhance 
efforts at disease prevention or development of more effec-
tive treatments.
As previously mentioned, the specificity of antigen 
recognition and lymphocyte activation is a deﬁ  ning feature 
of the adaptive immune system (Murphy et al 2007). During 
maturation, developing B- and T-cells undergo random 
rearrangements of gene segments encoding their respective 
antigen receptors. These distinctive genomic sequences, in 
turn, result in highly individual antigen receptors expressed 
on the cell surface of the lymphocytes, ie, immunoglobulins 
(Ig) on B-cells, and T-cell antigen receptors (TCR). Since 
the avidity of these antigen receptors is determined by their 
structure, each individual lymphocyte can only engage a very 
limited number of distinct peptides. Thus, adaptive immune 
responses against any given antigen are characterized by 
initial activation of only the tiny proportion of lymphocytes 
whose surface Ig or TCR happen to have speciﬁ  city for this 
antigen. However, the subsequent ability of these individual 
cells to undergo multiple divisions (clonal proliferations) 
results in large numbers of functional lymphocytes sharing 
identical antigen receptors (daughter progeny) that have 
speciﬁ  city against the offending antigen (microbial or other 
exogenous peptides), and are capable of mounting an effec-
tive immune defense (usually). Because the antigen receptor 
sequences are deﬁ  nable by various cellular DNA and mRNA 
assays, it becomes possible to evaluate populations of lym-
phocytes to determine the proportion of these cells that have 
shared ancestors, as determined by commonality of antigen 
receptor sequences. Finding that a T- or B-cell inﬁ  ltrate is 
comprised of daughter progeny derived from a small number 
of clonally expanded lymphocyte founders (ie, mono- or 
oligoclonality) demonstrates that a peptide antigen has driven 
these cellular proliferations (Feghali-Bostwick et al 2007). 
In distinction, lymphocytes that are induced to undergo 
promiscuous proliferations by mechanisms independent of 
antigen receptor speciﬁ  city (eg, mitogens, growth factors), 
or nonspeciﬁ  cally recruited to an inﬂ  ammatory foci and 
sequestered there, will comprise cells lacking shared 
ancesters (ie, polyclonal populations).
The antigen receptor repertoires of lymphocytes in 
COPD patients have been analyzed in a limited number of 
studies. Sullivan et al examined T-lymphocytes isolated 
from emphysematous lung tissue and demonstrated these 
populations were comprised of oligoclonal T-cells (Sullivan 
et al 2005). This ﬁ  nding was echoed by Korn et al who fur-
ther showed that clonal expansions were most particularly 
pronounced among CD8+ T-lymphocytes, in both the lung 
and in the blood of chronic smokers (Korn et al 2005). 
Additionally, circulating T-lymphocytes and those isolated 
from COPD lungs frequently exhibit down-regulation of 
CD28, a co-stimulatory molecule, which, in turn, is another, 
if less immediately evident consequence of chronic antigen 
exposure and repeated cell divisions (Sullivan et al 2005). 
CD28 down-regulation has been documented in a number 
of chronic inﬂ  ammatory syndromes including autoimmune 
diseases (Schirmer et al 1998) and lung allograft rejection 
(Studer et al 2008).
The origin of the peptide antigen(s) responsible for initiating 
this inﬂ  ammatory cascade remains speculative at this time. 
While there are numerous possibilities, a few of the seemingly 
more likely potential antigens will be discussed here:International Journal of COPD 2008:3(4) 535
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Microbial peptide antigens
The hypothesis that chronic or recurrent microbial infec-
tions in patients could be the source of the COPD antigenic 
stimulus is particularly attractive (Figure 3). Bacterial 
colonization of the airways in COPD patients with even 
mild airﬂ  ow obstruction is frequent (Soler et al 1999; Sethi 
et al 2006), and hence these particular microbes seem to be 
likely suspects as the source of disease-causing exogenous 
antigens. These bacterial colonizations are associated with 
recurrent COPD exacerbations, more rapid declines in lung 
function, and are correlated with a number of inﬂ  ammatory 
markers in sputum and in BAL (Hill et al 2000; Patel et al 
2002; Wilkinson et al 2003; Banerjee et al 2004).
Patients with COPD are also more susceptible to viral 
infections, and childhood viral infections have even been 
speculated to predispose individuals for development of 
COPD (Samet et al 1983). A small number of studies have 
found evidence that various viral infections may be associ-
ated with COPD, notably including a report that severe 
emphysema was associated with up to 40-fold greater 
prevalence of adenoviral E1A protein expression in alveolar 
epithelial cells (Retamales et al 2001).
Pneumocystis jiroveci is another organism that has been 
implicated in the pathogenesis of COPD. This organism has 
been reported to colonize 36% of lung tissues from patients 
with end-stage COPD versus 5% of specimens from healthy 
controls or those with less severe disease (Morris et al 
2004). Smokers infected with Human Immuno-deﬁ  ciency 
Virus (HIV) also appear to have accelerated development 
of emphysema, particularly in those that also have high 
CD8+ lymphocyte counts in BAL ﬂ  uid (Diaz et al 2000). 
Pneumocystis colonization in lungs of rhesus macaques 
infected with Simian Immunodeﬁ  ciency Virus (SIV) gener-
ated CD8-lymphocyte and neutrophil predominant cellular 
inflammation in association with progressive airflow 
limitation and local increases in IL-8, IFN-γ, and TNF-α, 
reminiscent of the findings in emphysematous patients 
(Norris et al 2006). These clinical and experimental results 
interestingly raise the possibility that Pneumoncystis and/or 
HIV (or perhaps other relatively indolent organisms) may be 
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Figure 3 Schema depicting the proposed role of microbial organisms in propagating pathogenic mechanisms in COPD.International Journal of COPD 2008:3(4) 536
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capable of contributing to the pathogenesis of lung disease, 
and obviously warrant further study.
Tobacco smoke related peptides
Exogenous antigens could plausibly be among the complex 
constituents of the tobacco smoke per se. Early reports noted 
tobacco glycoprotein (TGP), a polyphenol-rich glycoprotein 
isolated from cured tobacco leaves, could stimulate T-cell 
proliferation and activation in cell culture (Francus et al 
1988). Nonetheless, to our knowledge there is no conclusive 
evidence directly linking TGP or other components of smoke 
to cellular immune activation in COPD. Furthermore, the 
persistence of intrapulmonary inflammation long after 
smoking cessation argues against the dependence of COPD 
on antigenic stimulation provided by a smoke constituent, 
unless an immune response initially triggered by such an 
antigen subsequently generalized to include self-antigens 
(see below).
Tobacco smoke, as well as some other air pollutants, 
also contains highly reactive substances that are capable of 
chemical modiﬁ  cation of pulmonary proteins (eg, glycosolation, 
oxidation). Although not yet demonstrated, it is also plausible 
that some lung proteins altered by these processes could 
subsequently act as haptens, or even be so changed they are no 
longer recognized as “self       ” by immune cells and, thus provoke 
autoimmune responses.
Elastin peptides
A recent report has proposed that elastin peptides could be 
antigens that drive adaptive immune responses in COPD 
(Lee et al 2007). Elastin is an important extracellular matrix 
protein that helps maintain the structural integrity of the 
lung and other tissues. Under pathologic circumstances, 
elastin is degraded and digested by matrix MMP, which, 
as noted previously, have been shown to have increased 
activity in advanced emphysema. Elastin fragments stimulate 
monocyte chemotaxis and disease progression in a cigarette 
smoke model of murine emphysema (Houghton et al 2006). 
Circulating T-lymphocytes from COPD patients have 
recently been found to proliferate and secrete increased 
amounts of IFN-γ and IL-10 in co-incubations with elastin 
digestion fragments, and circulating antielastin antibodies 
were also present in these subjects (Lee et al 2007). The 
role of adaptive immune responses to elastin in development 
of COPD remains an intriguing area for further investiga-
tion. However, ﬁ  ndings elsewhere of analogous anti-elastin 
reactions in varied immune syndromes and some normal indi-
viduals, as well as demonstrations of multiple intracellular 
autoantigens in COPD patients (Feghali-Bostwick et al 2008) 
may indicate that the anti-elastin responses are not necessarily 
all-encompassing elements of disease pathogenesis.
Other autoantigens
Autoreactivity can also arise in the course of immune responses 
that were initially and more appropriately directed against 
exogenous antigens (eg, inhaled proteins or microbes). In some 
cases it appears that the molecular characteristics of the inciting 
antigen resemble or “mimic” those of self-determinants, which 
then become targets of immune responses that were initially 
triggered and fueled by the exogenous antigen (Oldstone et al 
2005). In addition, highly focused and appropriate responses 
against foreign antigens can spread to include targeting of 
otherwise quiescent self-antigens by functional errors of 
speciﬁ  city or “epitope spreading” (Figure 4) (Vanderlugt and 
Miller 2002). As previously described, the lower airways 
of COPD patients are frequently colonized and/or infected 
with various microbes (Soler et al 1999; Sethi et al 2006) 
that are known to be capable of immune activation (Adlovitz 
et al 2006). Thus, adaptive immune responses that arose 
to eradicate these organisms could ultimately lead to self-
reactivity by processes of microbial mimicry and/or epitope 
spreading, particularly in patients with chronic exposure to 
these organisms (Oldstone et al 2005; Vanderlugt and Miller 
2002; Croxford et al 2002).
Another potential mechanism that could conceivably 
account for auto-reactive adaptive immune activation in 
COPD stems from alterations of phagocytic functions and 
antigen processing. Abnormal or ineffective clearance 
of apoptotic cells and cellular debris (ie, “efferocytosis”) 
(Vandivier et al 2006), resulting in defective phagocytosis 
of apoptotic bodies and/or other particulates, have been 
linked to the development of autoimmunity (Cline and Radic 
2004). Hodge et al have shown that alveolar macrophages 
harvested from the BAL ﬂ  uid of patients with COPD had an 
impaired ability to phagocytose apoptotic epithelial cells in 
vitro (Hodge et al 2003).
Certain, otherwise perplexing clinical features of COPD 
could be explicable by an autoreactive pathogenesis. The 
development of typical autoimmune syndromes in human 
patients (as well as experimental animal models) seems 
to involve complex interactions between environmental 
factors (eg, cigarette smoke and/or possibly microbes) and 
genetic backgrounds. If also true in COPD, previously 
reported familial predilections, as well as the considerable 
inter-individual variability for disease susceptibility 
with equivalent smoking exposures, could be explained. International Journal of COPD 2008:3(4) 537
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Moreover, fully developed autoimmune responses tend to be 
self-perpetuating, a possible mechanism for persistence (and 
progression) of COPD despite smoking cessation.
T -cell mediators and COPD
Cytokines and chemokines are extracellular signaling 
proteins that mediate the effector functions of a variety of 
inﬂ  ammatory cells. A number of putative effector molecules 
have been implicated in the pathogenesis of COPD, and it 
is likely that an imbalance between the various pro- and 
anti-inﬂ  ammatory mediators may play a part in the develop-
ment of disease. This chronic pro-inﬂ  ammatory cytokine/
chemokine milieu could also contribute to the apparent sus-
ceptibility of patients suffering from COPD to bronchogenic 
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Figure 4 Mechanisms of infection-induced autoimmunity.   After a microbial infection, activated microbe-speciﬁ  c TH1 (mTH1) cells migrate to the infected organ. A Molecular 
mimicry describes the activation of crossreactive TH1 cells that recognize both the microbial epitope (mTH1) and the self epitope (sTH1) (a). Activation of the crossreactive 
T cells results in the release of cytokines and chemokines (b) that recruit and activate monocytes and macrophages, which mediate self-tissue damage (c). The subsequent 
release of self-tissue antigens and their uptake by APCs perpetuates the autoimmune disease (d). B Epitope spreading involves a persistent microbial infection (a) that causes 
the activation of microorganism-speciﬁ  c TH1 cells (b,c), which mediate self-tissue damage (d).   This results in the release of self peptides (e), which are engulfed by APCs and 
presented to self-reactive TH1 cells (f). Continual damage and release of self peptides results in the spread of the self-reactive immune response to multiple self-epitopes (f).
C Bystander activation is the nonspeciﬁ  c activation of self-reactive TH1 cells. Activation of microorganism-speciﬁ  c TH1 cells (a,b) leads to inﬂ  ammation (c,d) and results in the 
increased inﬁ  ltration of T cells at the site of infection and the activation of self-reactive TH1 cells by TCR-dependent and –independent mechanisms (e) Self-reactive T cells 
activated in this manner mediate self-tissue damage and perpetuate the autoimmune response (f). D Cryptic antigen model describing the initiation of autoimmunity by dif-
ferential processing of self peptides. Following microbial infection (a) IFN-γ is secreted by both activated microbe-speciﬁ  c TH1 cells (b,c) and microbe-infected tissue cells 
(d). This activates APCs (e) and can lead to APC engulﬁ  ng self-antigens (f). Cytokine activation of APCs can induce increased protease production and different processing 
of captured self-antigens, resulting in presentation of cryptic epitopes. The presentation of these cryptic epitopes can activate self-reactive TH1 cells (g), leading to self-tissue 
destruction (h,i). APC, antigen-presenting cell; MHC II, major histocompatibility complex class II; TCR, T-cell receptor.
Reprinted with permission from Vanderlugt CL, Miller SD. 2002. Epitope spreading in immune mediated diseases: implications for immunotherapy. Nat Rev Immunol, 2:85–94. 
Copyright © 2002 Nature Publishing Group.International Journal of COPD 2008:3(4) 538
Gadgil and Duncan
carcinoma and cardiovascular disease (Coussens et al 2002; 
Lu et al 2006; Sin et al 2008).
A Th1 predominant cytokine secretion pattern (eg, 
IFN-γ) has been described in most studies using COPD 
clinical specimens (Majori et al 1999; Hodge G et al 2007), 
although Th2 biased responses (eg, IL-4, IL-10) have con-
versely also been reported (Barcelo et al 2006; Barczyk 
et al 2006). The seeming disparities among these studies 
may be due to patient heterogeneity in terms of disease 
severity (or medications) and confounding introduced by 
typically small sample sizes (ie, alpha and beta errors). As 
in most complex disease processes, moreover, simple or 
rigid attempts to classify COPD as a particular Th pattern 
is probably an oversimpliﬁ  cation. The mediator environ-
ment responsible for the pathogenesis of this disease 
probably involves signiﬁ  cant overlap between Th1 and 
Th2 cytokines.
While the potential contributions of speciﬁ  c mediators 
in COPD have been exhaustively described elsewhere 
(Chung, 2001; Reid and Sallenave, 2003), here we will 
comment on the roles of selected lymphocyte-associated 
mediators that have been particularly implicated in disease 
pathogenesis:
Interferon-gamma (IFN-γ)
Interferon-gamma is a pro-inﬂ  ammatory cytokine produced 
primarily by Th1/Tc1 lymphocytes and natural killer cells 
and, among other effects, this mediator is a potent stimulator 
of alveolar macrophages and epithelial cells. As previously 
noted, IFN-γ has been shown to be upregulated in lympho-
cytes isolated from emphysematous lung tissue samples 
(Grumelli et al 2004), bronchoalveolar lavage ﬂ  uid (Hodge 
et al 2007), peripheral blood (Majori et al 1999; Hodge 
G et al 2007), and IFN-γ secreting CD8+ T-cells are seen in 
increased frequency within sputum of patients with COPD 
(Tzanakis et al 2004). These and multiple other reports 
suggest that IFN-γ plays a major role in the development of 
COPD. In addition, clinical observations are also supported 
by ﬁ  ndings that IFN-γ over-expression in the lungs of mice 
promotes development of emphysema (Wang et al 2000). 
Among a complex constellation of effects, tissue injuries of 
COPD may be particularly promoted by IFN-γ through the 
release of MMP from activated macrophages, or via injury 
by CXC3R+ CD8-lymphoyctes induced by IP-10 and MIG.
Tumor necrosis factor-alpha (TNF-α)
TNF-α is a pro-apoptotic cytokine which has been shown 
to be elevated in the serum of patients with stable COPD 
(Keating et al 1996), and further increased during acute 
exacerbations (Aaron et al 2001). A TNF-α gene polymor-
phism resulting in increased TNF-α levels has also been 
described in a population that is uniquely susceptible to the 
development of COPD (Huang et al 1997; Sakao et al 2002), 
although other studies have not been able to corroborate this 
ﬁ  nding (Higham et al 2000; Ferrarotti et al 2003). Interest-
ingly, serum concentrations of TNF-α, as well as TNF-α 
secretion by monocytes, is particularly robust in the subset 
of COPD patients with weight loss or cachexia (Di Francia 
et al 1994; De Godoy et al 1996; Pitsiou et al 2002). It has 
therefore been hypothesized that TNF-α contributes to the 
systemic manifestations of emphysema, particularly muscle 
wasting and limitations in exercise tolerance.
In the context of COPD histopathology, the effects of 
TNF-α could explain the cellular apoptosis observed in the 
alveolar wall among emphysematous lung tissue sections. 
TNF-α also induces the production of interleukin-8 (IL-8) and 
MMP through the induction of nuclear factor-κB. Overexpres-
sion of TNF-α in the lungs of mice results in the development 
of classic pathologic features of emphysema (Fujita et al 2001). 
Studies performed in TNF-receptor knockout mice using a 
cigarette smoke-induced model of emphysema generated a 
lesser degree of lung disease compared to wild-type animals 
(Churg et al 2004). However, TNF blockade with Inﬂ  iximab, 
an anti-TNF antibody, did not result in apparent beneﬁ  t, with 
respect to lung function, in patients with moderate to severe 
COPD, although additional evaluation may be necessary to 
evaluate whether selected subpopulations (eg, those with 
cachexia) could speciﬁ  cally beneﬁ  t (Rennard et al 2007).
Interleukin-1β (IL-1β)
IL-1β has functional similarity to TNF-α, and is a potent 
stimulator of alveolar macrophages. This mediator incites 
the production of a number of pro-inﬂ  ammatory mediators 
implicated in COPD pathogenesis including IL-2,-6,-8, 
RANTES, GM-CSF, IFN-γ, and TNF-α (Chung et al 2001). 
IL-1β also appears to be important in the regulation of elas-
tolytic proteases, including MMP-9, which could play a role 
in the development of emphysema. IL-1β/TNF-α double 
receptor knockout mice demonstrated progressive and more 
severe emphysema in response to intratracheal instillation 
of neutrophil elastase than cytokine single knockouts, or 
wild-type mice (Lucey et al 2002).
Interleukin-6 (IL-6)
Increased IL-6 levels have been found in induced sputum, 
exhaled breath condensates, and bronchoalveolar lavage ﬂ  uid International Journal of COPD 2008:3(4) 539
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from patients with COPD (Bhowmik et al 2000; Song et al 
2001; Bucchioni et al 2003). IL-6 is another mediator with 
numerous, varied and generally proinﬂ  ammatory effects. The 
precise role that IL-6 may play in the development of COPD 
is still unclear, but measures of this mediator may have utility 
as a biomarker of disease and inﬂ  ammation.
Interleukin-8 (IL-8)
The C-X-C chemokine IL-8 is a potent neutrophil and 
lymphocyte chemoattractant that is elaborated by diverse 
parenchymal and immune effector cells, including monocytes 
and lymphocytes (Hitomi et al 2004). As neutrophils comprise 
the predominant inﬂ  ammatory cell in COPD airspaces and, as 
noted earlier, lymphocytic inﬁ  ltrates within lung tissue per se are 
highly correlated with disease severity, it follows that IL-8 could 
play a part in the development of emphysema. IL-8 levels are 
increased in sputum of patients with COPD (Keatings et al 1996; 
Yamamoto et al 1997), and are further augmented during disease 
exacerbations, presumably in association with neutrophilic 
inﬂ  ammation triggered by bacteria (Crooks et al 2000; Aaron 
et al 2001; Gompertz et al 2001). Airway microbes induce IL-8 
secretion by epithelial cells, and levels of this cytokine have 
been shown to correlate with airway bacterial load (Hill et al 
2000; Patel et al 2002). Interestingly, blocking antibodies to 
IL-8 only led to a modest reduction in the neutrophilic inﬂ  am-
mation (Beeh et al 2003). This suggests that other chemotactic 
agents are also involved, and blocking IL-8 alone would not be 
expected to bring about a signiﬁ  cant clinical effect. On the other 
hand, blocking IL-8 receptors, (eg, CXCR2) that mediate the 
chemotactic responses of both IL-8 and other CXC chemokines 
may represent a more useful therapeutic target.
Interleukin-13 (IL-13)
IL-13 has been implicated in mucous hypersecretion and 
is thought to provoke the differentiation of goblet cells 
via EGFR (Shim et al 2001). Plasma levels of IL-13 have 
recently been shown to be inversely related to FEV1 (% of 
predicted), and proportional to the severity of gas exchange 
abnormality as deﬁ  ned by diffusion capacity (% DLCO) in 
COPD patients (Lee et al 2007). The ﬁ  nding that overexpres-
sion of IL-13 in murine lungs results in emphysema (Zheng 
et al 2000), validates the notion that IL-13 could play a role in 
the pathogenesis of this disease, particularly among patients 
with a bronchitic-predominant phenotype.
Conclusions
COPD is a complex syndrome with poorly understood 
pathophysiologic determinants. The adaptive immune system 
appears to actively participate in disease development and 
progression by elaboration of cytokines and other mediators, 
and likely too by production of injurious autoantibodies. 
CD8+ lymphocytes may be the predominant cellular element 
for direct mediation of tissue injuries, but the importance 
of CD4+ lymphocytes in orchestrating the inﬂ  ammatory 
response and facilitating autoimmune humoral responses also 
appears to be considerable. Identiﬁ  cation of the antigen(s) 
responsible for the adaptive immune activation of COPD is 
an important goal of future research. Although many potential 
antigens have been hypothesized, microbes may be among 
the most likely source.
Better understanding of T-cell and other adaptive immune 
processes in COPD pathogenesis will eventually lead to the 
development of more selectively targeted and rational disease 
interventions. Given the awesome morbidity and mortality of 
COPD, and the generally limited effectiveness of currently 
available treatments, innovative approaches with greater 
therapeutic effectiveness are sorely needed, and would have 
profound clinical importance.
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